Table 4 Effect of the intervention on lymphocyte subset percentages.
Control (n = 25), mean (± SD) | NBIW (n = 25), mean (± SD) | Between-group comparison (4 weeks) | Within-group comparison | ||||||
|---|---|---|---|---|---|---|---|---|---|
p | d or r | Effect size | p | ||||||
Control | NBIW | ||||||||
CD3+ | % | Baseline | 73.936 ± 6.476 | 0.3633 | 0.09 | – | 0.0044** | 0.0834 | |
Week 4 | 72.460 ± 6.052 | 72.998 ± 6.561 | |||||||
CD4 + | % | Baseline | 51.861 ± 7.358 | 0.0395* | 0.22 | Small | 0.0076** | 0.6514 | |
Week 4 | 50.025 ± 6.382 | 51.563 ± 7.453 | |||||||
CD4+CD45RA+ | % | Baseline | 43.172 ± 11.520 | 0.1166 | − 0.14 | – | 0.9746 | 0.0062** | |
Week 4 | 43.142 ± 12.323 | 41.448 ± 11.545 | |||||||
CD8+ | % | Baseline | 12.326 ± 5.408 | 0.1815 | − 0.17 | – | 0.0065** | 0.8746 | |
Week 4 | 13.382 ± 5.743 | 12.416 ± 5.927 | |||||||
CD8+CD28+ | % | Baseline | 73.261 ± 12.081 | 0.7982 | − 0.04 | – | 0.2641 | 0.4926 | |
Week 4 | 72.256 ± 13.544 | 72.314 ± 12.797 | |||||||
CD16+CD56− | % | Baseline | 0.719 ± 0.431 | 0.1424 | − 0.21 | Small | 0.1935 | 0.0017** | |
Week 4 | 0.587 ± 0.405 | 0.500 ± 0.355 | |||||||
CD16−CD56+ | % | Baseline | 4.456 ± 3.128 | 0.8823 | − 0.02 | – | 0.7672 | 0.3817 | |
Week 4 | 4.570 ± 3.418 | 4.477 ± 2.966 | |||||||
CD16+CD56+ | % | Baseline | 7.868 ± 3.198 | 0.3958 | − 0.16 | – | 0.2406 | 0.7995 | |
Week 4 | 8.472 ± 2.885 | 8.008 ± 2.993 | |||||||
CD20+ | % | Baseline | 15.623 ± 4.726 | 0.8625 | − 0.01 | – | 0.0366* | 0.0222* | |
Week 4 | 16.698 ± 5.421 | 16.630 ± 5.203 | |||||||